UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
MAY 20, 2008
Date of Report (Date of earliest event reported)
MIV THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Nevada | 000-30453 | 91-0809204 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
Unit 1, 8765 Ash Street, Vancouver, British Columbia, Canada | V6P 6T3 | |
(Address of principal executive offices) | (Zip Code) |
(604) 301-9545
Registrant's telephone number, including area code
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
__________
TABLE OF CONTENTS
Item | Description |
| |
|
|
|
|
__________
- 2 -
FORWARD-LOOKING STATEMENTS
Much of the information included in this Current Report on Form 8-K (the "Current Report") includes or is based upon estimates, projections or other "forward looking statements". Such forward looking statements include any projections or estimates made by us and our management in connection with our business operations. These statements relate to future events or our future financial performance. In some cases you can identify forward-looking statements by terminology such as "may", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "potential" or "continue or the negative of those terms or other comparable terminology. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance sugge sted herein. Such estimates, projections or other forward looking statements involve various risks and uncertainties and other factors that may cause our or our Company's actual results, levels of activities, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We caution the reader that important factors in some cases have affected and, in the future, could materially affect actual results and cause actual results to differ materially from the results expressed in any such estimates, projections or other forward looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to co nform those statements to actual results.
SECTION 8 - OTHER EVENTS
As previously disclosed by MIV Therapeutics, Inc. (the "Company") by way of Current Report on Form 8-K dated October 9, 2007, on or about October 1, 2007, the Company was served with a Summons and Complaint for an action brought by Chimex Hong Kong Incorporated Limited, Vascore Scientific Co., Ltd. and Vascore Medical (Suzhou) Co., Ltd. in New York state court against the Company and certain of its officers and directors, Alan P. Lindsay, Mark Landy, and Patrick A. McGowan (collectively, the "Complaint").
The Complaint alleged breach of contract, fraud, fraudulent concealment, negligent misrepresentation, unjust enrichment and conspiracy claims in connection with the previously disclosed (by way of the
Company's Current Report on Form 8-K dated August 31, 2007) termination of that certain "Equity Transfer Agreement", dated for reference effective on September 5, 2006.
The Company learned on May 20, 2008 that by Orders, dated March 31, 2008, the New York state court dismissed all the claims against the Company and its subject officers and directors for lack of personal jurisdiction.
- 3 -
SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01 Financial Statements and Exhibits.
(a) Financial statements of businesses acquired.
Not applicable.
(b) Pro forma financial information.
Not applicable.
(c) Shell company transactions.
Not applicable.
(d) Exhibits.
Not applicable.
__________
- 4 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MIV THERAPEUTICS, INC. | |
DATE: May 22, 2008. | By: s/s "Dr. I. Mark Landy" |
__________
- 5 -